AriBio completes treatment phase of Phase 3 Alzheimer’s trial

AriBio says it has finished the treatment phase of its global Phase 3 POLARIS-AD trial of AR1001 in early Alzheimer’s disease, moving the study into database lock and statistical analysis. Topline results are expected in Q4 2026, with detailed data planned for presentation at CTAD 2026 in Boston.

Why it matters: - AriBio’s AR1001 trial has reached a key late-stage milestone, putting the drug one step closer to readout in early Alzheimer’s disease. - The study’s outcome could shape future regulatory and commercialization plans for AR1001 and determine whether the program advances. - The extension phase is still collecting long-term safety and efficacy data, which could add context to the main trial results.

What happened: - AriBio completed the treatment phase of POLARIS-AD, its global Phase 3 registration trial of AR1001 in patients with early Alzheimer’s disease. - The last patient finished the scheduled four-week post-treatment safety follow-up visit on July 27, 2026. - The study has now moved into data cleaning, validation, database lock and statistical analysis. - AriBio plans to announce topline efficacy and safety results in Q4 2026. - Detailed Phase 3 results are planned for presentation at CTAD 2026 in Boston, beginning Nov. 16, 2026.

The details: - POLARIS-AD enrolled 1,535 patients across about 230 clinical trial sites in 13 countries, including the U.S., Europe, South Korea and China. - The trial was conducted as a randomized, double-blind, placebo-controlled Phase 3 study. - Participants received AR1001 or placebo for 52 weeks with clinical, functional and biomarker assessments during treatment. - A total of 1,348 participants completed the 52-week treatment period by the end of June 2026. - AriBio is reviewing clinical data collected from sites worldwide before final database lock. - The company plans to move forward with pre-specified statistical analyses after final review of data queries and safety information. - The optional long-term open-label extension continues after the main study. - 95.5% of eligible participants entered the extension phase, and more than 1,250 participants are currently receiving treatment and follow-up assessments. - The extension study is scheduled to end in July 2027. - AriBio says the extension is expected to provide additional long-term safety and efficacy data for future regulatory and commercialization planning. - AR1001 is an investigational once-daily oral small molecule being developed for Alzheimer’s disease and other neurodegenerative disorders. - AR1001 is a blood-brain barrier-penetrant PDE5 inhibitor designed to modulate NO–cGMP signaling and affect pathways tied to cerebral perfusion, neuroprotection, neuroinflammation and tau phosphorylation. - AR1001 has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.

Between the lines: - The completion of the treatment phase suggests AriBio is entering the critical evidence review period after a large, geographically diverse trial. - High extension-phase retention may signal sustained participant engagement, which can help support longer-term follow-up data. - The company’s immediate focus is on data integrity and analytical accuracy before releasing results.

What’s next: - AriBio will finish database lock and complete statistical analysis. - The company will then publish topline efficacy and safety data from the 52-week study. - CTAD 2026 is expected to be the first major venue for detailed Phase 3 results. - The extension study will continue through July 2027 and may inform later-stage regulatory planning.